Monte Rosa Therapeutics, Inc. (GLUE) Net margin 2024–2025
Monte Rosa Therapeutics, Inc. (GLUE) net profit margin by fiscal year — reported net income divided by reported revenue.
-58.8%FY2025 · since FY2024: -179.0% → -58.8%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -58.8% | +120.2 pp |
| FY2024 | -179.0% | — |
Net margin = reported net income ÷ reported revenue for the same fiscal year. Loss years show as a negative margin.
Source: SEC XBRL filings · For reference only · Not investment advice
More GLUE financial trends
GLUE RevenueGLUE Net incomeGLUE Gross profitGLUE Gross marginGLUE Operating incomeGLUE Operating marginGLUE Operating cash flowGLUE Free cash flowGLUE Capital expendituresGLUE Return on equityGLUE Stock buybacksGLUE Dividends paidGLUE Total assetsGLUE Total liabilitiesGLUE Shareholders’ equityGLUE overview →